Bioengineering for Girls Partners + Advisors

Cherié Butts, Ph.D. Cellular Immunologist, Biogen

Cherié Butts (R+D Strategy and Portfolio Leadership) is a cellular immunologist who serves as Portfolio Lead for NeuroImmunology + Acute Neurology at Biogen (Cambridge, Mass.). She obtained undergraduate and graduate degrees from The Johns Hopkins University. Her pre-doctoral studies characterized anti-tumor immune responses in ovarian cancer patients and postdoctoral studies at the National Institutes of Health examined neuroendocrine regulation of innate immunity. She continued this work at the US Food and Drug Administration, taking on additional responsibilities of evaluating drug and biologics applications. She now leads therapeutic and disease area strategy to help scientists and clinicians appreciate how assets address a specific unmet medical need for patients afflicted with debilitating conditions. She is passionate about ensuring individuals from all backgrounds contribute to the furtherance of biomedical research and works with professional societies, scientific and professional development organizations, and biomedical research institutions to do so. She currently serves on the Board of Overseers and Research Oversight Committee of Beth Israel Deaconess Medical Center and Board of Directors of Keystone Symposia and is Adjunct Associate Professor at University of Maryland.

Meena Subramanyam, Ph.D. VP + Global Program Leader, Takeda Pharmaceuticals

Dr. Meena Subramanyam is vice president and global program Leader in the gastroenterology division at Takeda Pharmaceuticals. In this capacity, Dr. Subramanyam oversees the strategic development of therapeutic assets for gastric motility indications. Previously, Dr. Subramanyam was vice president at Biogen in Cambridge, Mass., in the Global Biomarker Discovery and Development Division where she held broad responsibilities for developing the biomarker and diagnostics strategy for pipeline products in clinical development. Dr. Subramanyam has over 20 years of experience in the Biotechnology industry. She served as the chair of the National Biotechnology Conference in 2017, and as chair of the BIOTEC section of the American Association of Pharmaceutical Scientists. She also serves as a member of the Biotechnology Industrial Advisory Board of Northeastern University in Boston. Dr. Subramanyam has authored several scientific publications and white papers on topics related to therapeutic drug development.

Robert Truog, M.D. Pediatric Intensive Care Specialist, Boston Children’s Hospital Professor, Harvard Medical School Dr. Robert Truog is the Frances Glessner Lee professor of medical ethics, Anaesthesiology & Pediatrics at Harvard Medical School, where he serves as Director of the Center for Bioethics, leading educational and academic initiatives across the medical school. He has practiced pediatric intensive care medicine at Boston Children’s Hospital for more than 30 years, including serving as chief of the division for more than a decade. He has published more than 300 articles and books in bioethics and related disciplines, including “ Talking with Patients and Families about Medical Error ” (2010, Hopkins) and “ Death, Dying, and Organ Transplantation ” (2012, Oxford). In 2013 he was honored with the Spinoza Chair at the University of Amsterdam.

Made with FlippingBook Annual report